drugset
drugset / Trial / NCT07658352

A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

NCT07658352 ↗

Phase 1/2 Not yet recruiting 114 enrolled Shanghai Helioson Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, first-in-human dose escalation and dose expansion Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HP-002 in patients with relapsed or refractory B-Cell Non-Hodgkin Lymphoma This study consists of two phases: a dose-exploration phase and a dose-expansion phase. The safety and tolerability of HP-002 will be evaluated in Phase 1 study, as well as the maximum tolerated dose (MTD) and the recommended dose level for Phase 2 study will be determined. The efficacy of HP-002 will be evaluated in Phase 2 study.

Timeline

Start
2026-06-26
Primary completion
2029-06-26
Completion
2031-06-26

Drugs

EvaluationDrugModalityDoseRoute
Subject HP-002 Unknown — —

Indications

B-cell non-Hodgkin lymphoma